Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients

The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Marina Alexandre, Gérôme Bohelay, Thomas Gille, Christelle Le Roux-Villet, Isaac Soued, Florence Morin, Frédéric Caux, Sabine Grootenboer-Mignot, Catherine Prost-Squarcioni
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2022-04-01
Серии:Frontiers in Immunology
Предметы:
omalizumab (Xolair)
mucous membrane pemphigoid (MMP)
bullous pemphigoid (BP)
autoimmune bullous diseases (AIBDs)
autoimmune skin diseases
Immunoglobulin E (IgE)
Online-ссылка:https://www.frontiersin.org/articles/10.3389/fimmu.2022.874108/full
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы